News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article analyzes Absci's financial health, specifically its cash burn rate and cash reserves, to assess its ability to fund operations and future growth. It examines the company's current cash runway, which is estimated to be over two years based on recent expenditures. The …
Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This …
Absci Corp.'s Q2 earnings call highlighted promising interim Phase I data for its flagship antibody ABS-201, showing favorable safety, tolerability, and a long half-life. The company's financial position has been significantly strengthened by a recent $100 million financing, including a $40 million strategic investment …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …
This page provides news and articles related to Absci Corp (ABSI), a company specializing in generative AI for drug discovery. It highlights Absci's stock data and features an article discussing a major IPO targeting the healthcare AI sector, which could influence companies like Absci. …
BTIG Research has reaffirmed its "Buy" rating for Absci (NASDAQ:ABSI) and set a $13.00 price target, suggesting a potential upside of over 38%. This aligns with the overall positive sentiment from analysts, with eight recommending a "Buy" and one a "Sell," leading to a …
TD Cowen has reiterated its Buy rating for Absci Corp (ABSI.US). The firm did not specify any changes to its price target in this update.
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …
Absci Corp (ABSI) stock tumbled 16.6% in after-hours trading after the company reported second-quarter 2026 financial results that significantly missed revenue and earnings expectations. Q2 revenue was $300,000, half of the previous year's $600,000 and well below the $1.01 million consensus estimate, while the …
Absci reported a narrower Q2 net loss of $25.2 million, or $0.23 per share, compared to $27.9 million, or $0.26 per share, in the prior year. Revenue for the quarter declined to $0.4 million from $1.9 million year-over-year. The company's cash and cash equivalents …
Absci Corp (ABSI) reported its Q2 2026 results, showing partner program revenue of $318K, a net loss of ($33.21M), and a diluted loss per share of ($0.21). The decline in revenue is attributed to milestone timing, while the company continues to invest in its …
Earnings Call Insights: Absci (ABSI) Q2 2026 MANAGEMENT VIEW * CEO Sean McClain said the company released “positive interim Phase I data” from the HEADLINE trial, adding “the data suggests the study drug was well tolerated with favorable safety and tolerability” and that “ABS-201's …
Absci (NASDAQ:ABSI) reported its quarterly earnings, missing analyst expectations with a loss of $0.21 per share against a consensus of $0.19, and revenue of $0.32 million, significantly below the $0.89 million forecast. Despite the financial miss, the company highlighted promising interim Phase 1 results …
Absci Corporation (ABSI) announced its Q2 2026 financial results, reporting a wider-than-expected loss of $0.21 per share against an estimated $0.20 loss. Revenue reached $318,000, significantly missing the $931,670 estimate and marking a 46.0% year-over-year decline. The company posted a net loss of $33.2 …
* Absci press release [https://seekingalpha.com/pr/20615676-absci-reports-business-updates-and-second-quarter-2026-financial-and-operating-results] (ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.21 misses by $0.01. * Revenue of $0.3M (-50.0% Y/Y) misses by $0.63M. * Cash, cash equivalents, and marketable securities as of June 30, 2026 were $201.1 million, compared to $125.7 million as …
Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …
Absci Corporation reported a widening net loss of $33.2 million for Q2 2026 and $62.8 million for the first half of 2026, primarily due to increased R&D spending on its lead antibody ABS-201. Despite declining partner program revenue, the company significantly strengthened its balance …
Absci Corp. is preparing to announce its second-quarter results, with analysts expecting a significant surge in revenue driven by recent partnership deals, despite a disappointing first quarter. Investors will be closely watching the AI-powered drug discovery company's ability to maintain revenue momentum from its …
Absci Corp (ABSI) is scheduled to release its Q2 2026 earnings on August 11, 2026, with revenue estimates at $1.17 million and earnings at $-0.2 per share. While analyst price targets suggest a significant upside, GuruFocus's GF Value indicates a substantial downside of over …
This article provides an earnings forecast for Absci Corp (ABSI), detailing its current earnings forecast score, average price target from analysts, and analyst ratings. It highlights that 10 analysts generally recommend a "Buy" for ABSI, with a target price of $9.00 and an expected …
This article from TradingKey provides current stock information for Absci Corp (ABSI), a biotechnology and medical research company. It includes the stock's current price, daily change, market capitalization, and indicates that more news, earnings, analyst ratings, and key developments will be available soon.
Absci Corp (ABSI) is scheduled to report its financial results post-market on August 11. Analysts expect the company to post a GAAP EPS of -$0.17 for the second quarter, with revenue projections around $2.31 million. The article provides details on the company's past earnings …
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained a target price of $16. This indicates the firm's continued confidence in the company's stock performance. Investors will likely view this as a positive signal regarding Absci's future outlook.
Absci Corporation (ABSI) generated $2.80 million USD in revenue last year, primarily from its Antibody-based Therapeutics segment. This represents a decrease from the previous year's $4.53 million USD. The United States was the company's largest regional contributor to revenue.
This article provides a detailed historical cash flow statement for Absci Corp (ABSI), covering operating, investing, and financing activities on a quarterly and annual basis. It includes key financial metrics like operating cash flow, net income, capital expenditures, and free cash flow over several …
This article analyzes the valuation of Absci Corp (ABSI), noting its current valuation score of 6.20 and ranking within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -9.18, indicating a significant deviation from its recent high and low. The …
This article provides a technical analysis of Absci Corp (ABSI), detailing its price momentum score, current trading range, and support/resistance levels. It also presents an analysis based on various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, offering a neutral signal for the …
This article details the shareholder structure of Absci Corp (ABSI), identifying major institutional holders and their proportion of shares. It breaks down shareholder types and provides a historical view of institutional holdings and recent shareholder activity with changes in their positions. The article also …
Search by ticker symbol or company name and select a result to open its chart.